The FDA approved Moderna's mFlusiva in August, and it's now available to adults 50 and older.

By Nancy Lapid Oct 7 (Reuters) - With all the dire predictions about AI's potential to wipe out humanity, today we highlight ...

LIBERTY met all primary/secondary endpoints, with lower 6-day TEAEs/ISRs/hypersensitivity (56.5% vs 91.4%) and systemic AEs ...

Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, ...

The FDA’s approval of an mRNA flu shot presents a new, long-awaited option—and raises big questions about the future of flu ...

Denise Fitzsimmons knew that removing the fast-growing lump above her eyebrow in 2024 didn’t eliminate the possibility that her melanoma could return. But a clinical trial at Penn Medicine offered the ...

No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.

Moderna (MRNA) stock rose after confirming Nasdaq-100 inclusion, even as Citi downgrades the stock on valuation concerns.

The FDA has approved mFlusiva, the first mRNA flu vaccine, for adults ages 50 to 64, but the CDC has not added it to its recommended list amid legal uncertainties and disruptions to the federal ...

People looking to get their annual flu shot this fall may find a new option alongside the usual vaccines: an mRNA flu shot. Not everyone is eligible, however.